Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions, including kidney stones (known as ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this ...

Source: Getty Images The procedure may be particularly efficacious for men with very large prostates. AMELIA ISLAND, FL—Prostate artery embolization (PAE) has been emerging as a minimally invasive ...

CHICAGO, Ill. (IVANHOE NEWSWIRE)- Benign prostatic hyperplasia, or BPH, is a natural enlargement of the prostate. 50 percent of men in their 50′s will have this condition, along with 80 percent of men ...